TMC Life Sciences which owns Thompson Hospital has reported an optimistic financial result for its YTD 2021, the group saw its revenue increase by 6% to RM201 million from RM190 million a year ago. This was attributed to higher case intensity handled and additional services provided by its healthcare business.
Overall EBITDA also to RM39 million from RM33.8 million due to higher revenue and lower costs, including lower selling and marketing expenses. On its expansion plans, the Thomson Hospital Kota Damansara (THKD) is now targeted to begin operations in Q3 of FY2022 due to delays following the implementation of MCO and different phases of National Recovery Plan. For Thomson Iskandar Medical Hub, work is currently ongoing.
Comparisingly, TMC highlighted that its outpatient attendance increased but inpatient admissions dropped, as isolation rooms were created to accommodate new infection control policies and elective cases were delayed to the surge in Covid-19 cases in the community. Despite the lower number of inpatient admissions, inpatient revenue increased due to higher case intensity handled.
Healthcare centres have been having struggling to manage during the pandemic with lockdowns and Covid-19 fears, however TMC has been one of the bright spots with its product offerings. The Group aims to be the “Integrated Healthcare System of Choice in Southeast Asia” and has plan to expand its flagship hospital, Thomson Hospital Kota Damansara to a 535-bed hospital with additional specialist centres, operating theatres, a cancer centre and a multi-storey carpark.
Additionaly, a new integrated medical hub – Thomson Iskandar – will be developed in the proposed Vantage Bay Healthcare City in bustling Johor Bahru. Located just off the Causeway linking Johor and Singapore, Thomson Iskandar will house a 500-bed tertiary hospital, specialist medical suites and related health and wellness facilities.
